AZD6140

Known as: AZD 6140, AZD-6140 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ticagrelor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist
Ticagrelor (AZD6140) is the first reversibly binding oral P2Y(12) receptor antagonist that blocks ADP-induced platelet… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
BACKGROUND P2Y(12) plays an important role in regulating platelet aggregation and function. This receptor is the primary target… Expand
Is this relevant?
2009
2009
Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model.
BACKGROUND Platelet activation and thrombus renewal are keys to intraluminal thrombus formation and progression of abdominal… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
PurposeTicagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist in development for reduction of… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
Review
2008
Review
2008
P2 receptors, platelet function and pharmacological implications.
ADP and ATP play a crucial role in platelet activation and their receptors are potential targets for antithrombotic drugs. The… Expand
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
OBJECTIVES In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute…
OBJECTIVES Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2007
Review
2007
Clopidogrel resistance?
Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective and irreversible blockade of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Review
2007
Review
2007
Dyspnoea after antiplatelet agents: the AZD6140 controversy.
Recent randomised studies suggest that experimental oral reversible platelet P2Y12 receptor inhibitor, AZD6140, causes dyspnoea… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
AIMS This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of… Expand
Is this relevant?